Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bausch Health Companies Inc BHC

Primary Symbol: T.BHC

Healthcare

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Add To Watchlist

Recent & Breaking News (TSX:BHC)

Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program

PR Newswire November 15, 2018

Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland

PR Newswire November 13, 2018

Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021

PR Newswire November 7, 2018

Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement

PR Newswire November 7, 2018

Bausch Health To Participate At The Stifel 2018 Healthcare Conference

PR Newswire November 7, 2018

Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults

PR Newswire November 7, 2018

Bausch Health Companies Inc. Announces Third-Quarter 2018 Results

PR Newswire November 6, 2018

Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States

PR Newswire October 30, 2018

Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors

PR Newswire October 30, 2018

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

PR Newswire October 29, 2018

Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud

PR Newswire October 24, 2018

Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships

PR Newswire October 23, 2018

Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference

PR Newswire October 15, 2018

Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6

PR Newswire October 12, 2018

Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology

PR Newswire October 11, 2018

Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting

PR Newswire October 8, 2018

Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults

PR Newswire October 8, 2018

Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology

PR Newswire October 2, 2018

Salix Resolves Legacy SEC Investigation With No Penalty

PR Newswire September 28, 2018

CORRECTING and REPLACING – Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

GlobeNewswire September 27, 2018